KALA BIO (NASDAQ: KALA) cuts its quarterly net loss by 89.5% in preliminary results

What happened

KALA BIO, Inc. (NASDAQ: KALA) reported a third-quarter 2026 net loss of approximately $0.8 million, down from $7.6 million a year earlier.

The company issued the preliminary, unaudited figures on Nov. 9 for the quarter ended Sept. 30. For the nine months ended Sept. 30, the net loss was approximately $4.0 million, compared with $27.7 million a year earlier.

KALA ended the quarter with approximately $7.0 million in cash, cash equivalents and short-term investments, and it has no debt.

Avi Minkowitz, who is both chief executive officer and chief financial officer, said the company cut its quarterly net loss by approximately 90% year over year. He said it continues to develop its new initiatives. He also thanked stockholders who attended the Nov. 3 annual meeting.

Key numbers

Metric	Latest	Change	Source
Net loss, third quarter (preliminary)	$0.8 million	from $7.6 million, -89.5%	SEC 8-K Exhibit 99.1 (change calculated by OptimistFi)
Net loss, nine months ended Sept. 30 (preliminary)	$4.0 million	from $27.7 million, -85.6%	SEC 8-K Exhibit 99.1 (change calculated by OptimistFi)
Cash, cash equivalents and short-term investments, Sept. 30, 2026	$7.0 million		SEC 8-K Exhibit 99.1
Debt, Sept. 30, 2026	None		SEC 8-K Exhibit 99.1

Read more: KALA BIO (KALA) company research

What KALA says it is building

The company calls itself a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry.

Its strategy has two parts. One is a proprietary biologics pipeline that includes its mesenchymal stem cell secretome (MSC-S) platform and product candidates with FDA Orphan Drug and Fast Track designations. The other is an AI platform-as-a-service business that deploys AI tools inside biotech and pharmaceutical client environments.

The AI side rests on an exclusive worldwide license from Younet for the Researgency AI research platform.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

Why it matters

OptimistFi has argued that KALA is a thinly capitalized turnaround option, not a revenue-compounding biopharma. In that view, its value depends on proving the new AI infrastructure business before cash and credibility run out. This release moves that view toward mixed.

On the plus side, OptimistFi calculates that the quarterly loss fell by $6.8 million, or 89.5%, from the third quarter of 2025. The nine-month loss fell 85.6%. A smaller loss and no debt slow the pace at which the balance sheet is used up.

A smaller loss is not proof that the AI business works, though. The company describes it as a platform it intends to build, so the test of that business is still ahead.

The $7.0 million cash balance is the other side of the ledger. It is the pool the company has on hand while it develops its initiatives, and it weighs more in the case than the loss comparison does.

Why the numbers are not final

KALA calls all of the results preliminary and unaudited. They depend on the financial close and a review by its independent registered public accounting firm. The company says final results in the Form 10-Q may differ.

The release says a delay in completing or filing the 10-Q could change what is reported. So could adjustments from the financial close and any later events found before filing.

For a holder, the 89.5% drop is an estimate until the quarterly report is on file.

What's next

KALA expects to file its Form 10-Q for the quarter ended Sept. 30, 2026 with the SEC on or about Nov. 16.

If the 10-Q matches the preliminary loss and cash figures, the smaller loss rests on reviewed numbers. If either figure moves, the turnaround reading weakens.

More from OptimistFi

• KALA stock: research and coverage of KALA BIO
• Stock research on every company OptimistFi covers

From OptimistFi Perps